Pharmaceutical companies have resorted to different ways to address the challenges posed by the COVID-19 pandemic with respect to supply chain risks including diversification of suppliers and sources.

GlobalData has conducted a survey to assess how companies addressed and monitored import/export and supply chain risks associated with coronavirus in the first and third quarters.

Import-exports and supply chain risks Q1 vs Q3

Monitoring of import/export and supply chain risks related to coronavirus: Q1 vs Q3

A majority 45% of the companies in Q1 opined that they do not have a dedicated team to address the risks, but they have committees/working teams that meet up regularly. The percentage declined marginally to 44% in Q3.

A dedicated team was available to address the risks at 38% of the companies in Q1, which declined to 35% in Q3.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Dependence on suppliers to identify the risks increased, from approximately 17% of the companies in Q1 to 21% in Q3.

The analysis is based on responses received from the Pharmaceutical Trade and Supply Chain Survey between 07 July and 30 July 2020.